BioNTech's Seoul Showdown: One Combination Could Redefine the Post-COVID Investment Thesis
Published on 09/03/2026 at 04:31 | Editorial boerse-global.de
The market's message over the past month has been remarkably clear: a halted colorectal cancer trial is a footnote, not a headline. Since BioNTech pulled the plug on its BNT122-01 study last Monday, the share price has actually climbed 2.3 percent — a muted reaction that speaks volumes about where investor attention now resides.
That focus lands squarely on Seoul, where from September 12-15 the company will present its first combination data set pairing pumitamig with the antibody-drug conjugate elfetabart drozuntecan at the IASLC World Conference on Lung Cancer. It marks the inaugural look at a PD-(L)1xVEGF bispecific immunomodulator alongside an ADC in lung cancer treatment — and, for many, the clearest test yet of whether BioNTech's oncology pivot can carry the valuation once COVID revenue fades.
A Rally Built on Shifting Priorities
The stock's resilience tells its own story. At Wednesday's close of €89.70, shares sit roughly 13.5 percent above levels seen after the second-quarter earnings release, and about 12.1 percent higher since Guido Oelkers was named incoming chief executive a month ago. The 50-day moving average sits about 7.4 percent below the current price, while the gap to January's 52-week high of €105.80 narrows to roughly 15 percent.
None of this is to suggest the underlying numbers were encouraging. Second-quarter revenue tumbled to €105.6 million from €260.8 million a year earlier — a 59 percent contraction — while the net loss widened to €820.8 million. Management slashed full-year guidance to a range of €1.6 billion to €1.9 billion. Yet the stock rallied anyway, buoyed by a war chest of €16.6 billion and a share buyback program of up to $1 billion that signals management's confidence in its own trajectory.
The market, in effect, has rotated. The colorectal setback is being treated as an isolated data point, while the broader narrative — a leadership transition and an oncology strategy increasingly trained on lung rather than bowel — takes precedence.
Should investors sell immediately? Or is it worth buying BioNTech?
The Pumitamig Question
For investors, the Seoul readout reduces to a single question: can pumitamig in combination with an ADC replicate the consistency across PD-L1 expression levels that the drug demonstrated as a third global data set at ASCO earlier this year?
The stakes are considerable. Pumitamig, developed jointly with Bristol Myers Squibb, represents BioNTech's most credible vehicle for offsetting the collapse in COVID vaccine sales. The ADC component, elfetabart drozuntecan, comes from the collaboration with Duality Biologics. Together, they form the centerpiece of a pipeline that must deliver — because with the legacy vaccine business shrinking as a revenue prop, clinical substance is the only thing underpinning the valuation.
The May ASCO presentation offered reason for optimism: phase 2 interim data showed pumitamig combined with chemotherapy achieved confirmed response rates of up to 72.7 percent in advanced non-small cell lung cancer, with a disease control rate of 100 percent. UBS responded by upgrading the stock from Neutral to Buy with a $135 price target. Should Seoul confirm those figures in the combination setting, the August rally — which was also fueled by positive phase 3 data for Moderna and Merck's personalized melanoma vaccine, validating the same mRNA mechanism — would likely extend.
Canaccord Genuity reiterated its Buy recommendation on August 19, lifting its price target to $142 and citing three key oncology readouts before year-end plus the impending CEO transition as catalysts. Further data points loom: an interim analysis of gotistobart in squamous non-small cell lung cancer, a phase 3 interim readout for BNT113 in head and neck tumors, and a primary analysis of TPAM in breast cancer.
Caution Hasn't Disappeared
The halted colorectal study, however, serves as a reminder that early-stage promise doesn't always translate. Should the Seoul data come in weaker than the ASCO results — or throw up unexpected safety signals — doubts would quickly surface about whether pumitamig's success transfers to more complex combination regimens.
Analyst sentiment has already cooled somewhat. Canaccord trimmed its price target to $136 from $142 in late August, following the trial discontinuation. Morgan Stanley had earlier reduced its target from $126 to $119 in early August, before the halt, while maintaining an Overweight rating. Neither move suggests a loss of fundamental conviction — rather, expectations are being recalibrated.
Leerink Partners struck a more bearish note on August 19, downgrading the stock with reference to weak revenue trends and broader risks facing the mRNA cancer vaccine class. Institutional positioning in the second quarter was similarly mixed: one major fund added to its stake while others trimmed meaningfully, and a board member sold a multi-million-euro share package.
BioNTech at a turning point? This analysis reveals what investors need to know now.
With 30-day annualized volatility running at 71 percent, the stock remains vulnerable to sharp moves in either direction — a reality that cuts both ways should Seoul disappoint.
The Road Beyond Seoul
The leadership transition, with Oelkers set to take the helm no later than February 1, 2027, functions more as a long-term strategic signal than a near-term catalyst. What matters now is whether the oncology data from South Korea validates the recovery that has taken hold since August.
If pumitamig and its ADC partner demonstrate consistent response rates with a manageable safety profile, the distance to that 52-week high leaves room for further upside. If the data falters, however, a re-rating of the entire oncology pipeline could follow — particularly as the COVID franchise continues to shrink as a revenue source.
The next concrete checkpoint is Seoul. The interim analyses for gotistobart, BNT113, and TPAM scheduled for the second half of the year will follow in turn. For now, the direction of BioNTech's stock hinges less on what happens in Mainz and more on what emerges from a conference hall in South Korea.
Ad
BioNTech Stock: New Analysis - 3 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
